Improved radioreceptor assay for the determination of plasma levels of dihydropyridine calcium channel blockers in humans.
Ways of improving sensitivity of the radioreceptor assay to determine the plasma levels of dihydropyridine calcium antagonists were investigated. Extraction of the drug from plasma with organic solvent was found to enhance the sensitivity of the assay (method 1). Alternatively, the inhibitory effect observed when plasma is added directly to the binding assay can be counteracted by increasing the amount of membranes in the assay (method 2). Plasma levels after single oral doses of nitrendipine and nicardipine were followed with method 1. Plasma levels of isradipine were measured with methods 1 and 2 and by mass fragmentography. The data confirm that nitrendipine plasma level kinetics vary widely from patient to patient, whereas for nicardipine the drug level profile is more homogeneous. The similarity of the data obtained from the radioreceptor assay and from mass fragmentography suggests the absence of any active metabolite of isradipine.
Quennedey
M C
MC
Institut de Pharmacologie, URA DO 589 CNRS, Strasbourg, France.
Ehrhardt
J D
JD
Welsch
M
M
Rouot
B
B
Schwartz
J
J
D000818:Animals; D002121:Calcium Channel Blockers / Q000032:analysis*; D004095:Dihydropyridines / Q000097:blood*; D017275:Isradipine; D008297:Male; D013058:Mass Spectrometry; D009529:Nicardipine / Q000097:blood; D009568:Nitrendipine / Q000097:blood; D011725:Pyridines / Q000097:blood; D011869:Radioligand Assay; D051381:Rats; D011919:Rats, Inbred Strains
D002121:Calcium Channel Blockers; D004095:Dihydropyridines; D011725:Pyridines; D009568:Nitrendipine; D009529:Nicardipine; D017275:Isradipine